Survivorship – Bladder / Ureter / Renal Pelvis Cancer

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

**ELIGIBILITY**

Bladder cancer 5 or more years after completion of treatment and NED (Patients with suspected or confirmed non muscle invasive bladder cancer are excluded from this algorithm)

**CONCURRENT COMPONENTS OF VISIT**

- Years 5-10
  - Annually:
    - History & physical exam
    - CMP, LDH, CBC with differential, and vitamin B12
    - Urine cytology
    - CT abdomen and pelvis with contrast or ultrasound abdomen every 2 years

- Years 11-20
  - Annually:
    - History & physical exam
    - BUN, creatinine, and vitamin B12
    - Urine cytology
    - Chest x-ray
    - CT abdomen and pelvis or ultrasound renal as clinically indicated

**SURVEILLANCE**

- **MONITORING FOR LATE EFFECTS**
  - Renal insufficiency
  - Ostomy or continence issues
  - Sexual health

- **RISK REDUCTION / EARLY DETECTION**
  - Patient education, counseling, and screening:
    - Lifestyle risk assessment
    - Cancer screening
    - HPV vaccination as clinically indicated (see HPV Vaccination algorithm)
    - Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management – HBV algorithm)
    - Consider cardiovascular risk reduction

  - Vaccinations as appropriate

- **PSYCHOSOCIAL FUNCTIONING**
  - Assess for:
    - Distress management (see Distress Screening and Psychosocial Management algorithm)
    - Body image
    - Financial stressors
    - Social support

**DISPOSITION**

- New primary or recurrent disease? Yes → Return to primary treating physician
  - No → Continue survivorship monitoring

- Refer or consult as indicated

**NED = no evidence of disease**

**CMP = complete metabolic panel**

**LDH = lactate dehydrogenase**

1 Obtain if patient has continent diversion

2 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

3 Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, prostate, and skin cancer screening

4 Consider use of Vanderbilt’s ABCDE’s approach to cardiovascular health

5 Based on Centers for Disease Control and Prevention (CDC) guidelines
SUGGESTED READINGS


This survivorship algorithm is based majority expert opinion of the Genitourinary Survivorship workgroup at The University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Katherine Gilmore, MPH (Cancer Survivorship)
William Graber, MD (Urology)
Ashish M. Kamat, MD (Urology)
Thoa Kazantsev, MSN, RN, OCN
Deborah A. Kuban, MD (Radiation Oncology Department)
Christopher Logothetis, MD (Genitourinary Medical Oncology)
William E. Osai, MSN, RN, FNP (Genitourinary Medical Oncology)
Raghu Vikram, MD (Abdominal Imaging Department)

\(^{1}\) Core Development Team
\(^{*}\) Clinical Effectiveness Development Team

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.